Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Barlesi

Showing results (41-50 of 84) with videos related to

Pageof 9
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2011
Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)F Barlesi, R Gervais, H Lena, et al.
ESMO Open|April 15, 2022
Postgraduate oncology educational shifts during the COVID-19 pandemic: results of faculty and medical student surveysA Moya-Plana, L Tselikas, O Lambotte, et al.
British Journal of Cancer|September 22, 2011
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)H LeCaer, F Barlesi, R Corre, et al.
Revue Des Maladies Respiratoires|March 28, 2016
[Oncogenic drivers in daily practice improve overall survival in patients with lung adenocarcinoma]C Fournier, L Greillier, F Fina, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2012
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trialM Reck, I Bondarenko, A Luft, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancerN Katakami, E Felip, D R Spigel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2016
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upS Novello, F Barlesi, R Califano, et al.
British Journal of Cancer|May 20, 2004
CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patientsJ-L Pujol, O Molinier, W Ebert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2013
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)S Ramalingam, J Crawford, A Chang, et al.
Cancer Immunology, Immunotherapy : CII|May 21, 2022
Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studiesV Moreno, E Calvo, M R Middleton, et al.
Pageof 9

Showing results (41-50 of 84) with videos related to

Sort By:
Pageof 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2011
Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)F Barlesi, R Gervais, H Lena, et al.
ESMO Open|April 15, 2022
Postgraduate oncology educational shifts during the COVID-19 pandemic: results of faculty and medical student surveysA Moya-Plana, L Tselikas, O Lambotte, et al.
British Journal of Cancer|September 22, 2011
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)H LeCaer, F Barlesi, R Corre, et al.
Revue Des Maladies Respiratoires|March 28, 2016
[Oncogenic drivers in daily practice improve overall survival in patients with lung adenocarcinoma]C Fournier, L Greillier, F Fina, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2012
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trialM Reck, I Bondarenko, A Luft, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancerN Katakami, E Felip, D R Spigel, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2016
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upS Novello, F Barlesi, R Califano, et al.
British Journal of Cancer|May 20, 2004
CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patientsJ-L Pujol, O Molinier, W Ebert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2013
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)S Ramalingam, J Crawford, A Chang, et al.
Cancer Immunology, Immunotherapy : CII|May 21, 2022
Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studiesV Moreno, E Calvo, M R Middleton, et al.
Pageof 9